Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
Latest Information Update: 17 Sep 2021
Price :
$35 *
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity; Sleep apnoea syndrome
- Focus Registrational; Therapeutic Use
- Acronyms SCALE; SCALE-Sleep Apnoea
- Sponsors Novo Nordisk
- 04 Apr 2016 Results (pooled analysis of this and other four trials, n = 5338) assessing neuropsychiatric Safety Profile presented at The 98th Annual Meeting of the Endocrine Society.
- 08 May 2015 According to the Novo Nordisk media release, further data from this and other three SCALE trials (see profile 193291, 193353 and 38848) expected to be presented and published in 2015.
- 08 May 2015 According to the Novo Nordisk media release, new data from a post-hoc analysis of this and other three SCALE trials (see profile 193291, 38848 and 193353) were presented at the European Congress on Obesity (ECO).